Mylan NV (NASDAQ:MYL) Pronounces EpiPen Shortages In Britain And Canada


The stock of Mylan NV (NASDAQ:MYL) closed at $40.63 losing 1.53% in yesterday’s trading session. The latest reports indicate that there is a shortage in the supply of EpiPen and that is specifically in Britain and Canada. Even with that said, it I crucial to disclose that it still available in the United States and this information was provided recently by the treatment’s manufacturer.

One of the most outstanding aspects about this medication lies in the fact that it in the fact that it is a potentially lifesaving dose and is administered via an automatic injector that a caregiver or patient can use in the course of a severe allergic reaction.

The spokesman for Pfizer Inc Steve Danehy while moving out of a business conference that was held recently had a number of things to talk about regarding the company’s progress as he addressed news reporters that were out to get his perspective.

According to him, the company was at the moment making efforts to ship the product adding that it was a good thing that there wasn’t a shortage of the product in the U.S which implied that patients were getting what they deserved in terms of accessing the right kind of medication.

He delved deeper into the matter to outline that Pfizer Inc (NYSE:PFE) had over the years delivered the global supply of EpiPens for Mylan and that was specifically from a facility situated close to St. Louis, Missouri.

Through an email, Danehy pointed out to the fact that Mylan was indeed the one in charge of managing the allocation of the EpiPen supply. It was great to a lot of people following closely on the latest developments to see light shed on the crucial matter.

However, the question that keeps popping up from time to time is regarding why the UK and Canada would to this point in time be still subjected to such a shortage to this point in time. Despite efforts by several journalists to get a Mylan spokeswoman to comment on that, uncertainty still continues to surround the matter.


Please enter your comment!
Please enter your name here